trial

The Effects of Cannabidiol and ∆-9-THC in Humans

NCTId NCT01180374
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Completed
Enrollment 27 (actual)
Sponsored by Yale University
Primary completion 2014-10-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Completed
Enrollment
27 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2010-02-01
Primary completion
2014-10-06
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
CannabidiolDelta-9-THC

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Mohini Ranganathan, M.D.Principal Investigator

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
27
Phase
EARLY_PHASE1
Primary Completion Date
2014-10-06
Status
COMPLETED
relationships
The graph out of here
drug
Cannabidiol
drug
Delta-9-THC
drug
lead_sponsor
Yale University
company
indication
Psychotic Disorders
indication
Healthy
indication
Marijuana Abuse
indication
investigator
Mohini Ranganathan, M.D.
person